Wuxi Biologics
Wuxi Biologics, also known as Wuxi AppTec, is a leading global contract research, development, and manufacturing organisation (CRDMO) headquartered in Wuxi, China. Established in 2010, the company has rapidly expanded its operational footprint across major regions, including the United States and Europe, positioning itself as a key player in the biopharmaceutical industry. Specialising in biologics, Wuxi Biologics offers a comprehensive range of services, from cell line development to commercial manufacturing. Its unique capabilities in integrated solutions and advanced technologies have set it apart in a competitive market. The company has achieved significant milestones, including numerous partnerships with top pharmaceutical firms, solidifying its reputation for excellence and innovation in drug development. With a commitment to quality and efficiency, Wuxi Biologics continues to drive advancements in the biopharmaceutical landscape.
DitchCarbon Score
How does Wuxi Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wuxi Biologics's score of 39 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Wuxi Biologics's reported carbon emissions
In 2023, Wuxi Biologics reported total carbon emissions of approximately 182,000 tonnes CO2e, comprising 32,687 tonnes from Scope 1, 149,229 tonnes from Scope 2, and 20,012 tonnes from Scope 3 emissions. This reflects the company's ongoing commitment to reducing its carbon footprint across all scopes. Wuxi Biologics has set ambitious long-term climate commitments, aiming for net-zero emissions by 2050. The company is actively working towards this goal, having committed to the Science Based Targets initiative (SBTi) in June 2023, which encompasses all scopes of emissions. In recent years, Wuxi Biologics has demonstrated a consistent reduction in its emissions intensity, achieving a Scope 1 and 2 emission intensity of about 0.000011 CNY per unit of revenue in 2022, down from 0.000021 CNY in 2019. This indicates a significant improvement in operational efficiency and a proactive approach to sustainability. Overall, Wuxi Biologics is focused on enhancing its environmental performance while contributing to global climate goals, reflecting its commitment to sustainable practices in the biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 11,042,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,361,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wuxi Biologics is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
